Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases

Guanqun Yang; Guanqun Yang; Ligang Xing; Ligang Xing; Xiaorong Sun; Xiaorong Sun

doi:10.3389/fimmu.2022.852811

Frontiers in Immunology (Mar 2022)

Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases

Guanqun Yang,
Guanqun Yang,
Ligang Xing,
Ligang Xing,
Xiaorong Sun,
Xiaorong Sun

Affiliations

Guanqun Yang: Cheeloo College of Medicine, Shandong University, Jinan, China
Guanqun Yang: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
Ligang Xing: Cheeloo College of Medicine, Shandong University, Jinan, China
Ligang Xing: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
Xiaorong Sun: Cheeloo College of Medicine, Shandong University, Jinan, China
Xiaorong Sun: Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

DOI: https://doi.org/10.3389/fimmu.2022.852811
Journal volume & issue: Vol. 13

Abstract

Read online

Brain metastases (BMs) in non-small-cell lung cancer (NSCLC) patients are associated with significant morbidity and poor prognosis. Immune checkpoint inhibitors (ICIs) have resulted in a paradigm shift in the management of advanced NSCLC. However, the value of ICIs in NSCLC patients with BMs remains unclear because patients with BMs are routinely excluded in numerous prospective trials on ICIs. Here, starting from the mechanisms of ICIs for BMs, we will reveal the value of ICIs by reviewing the efficacy and adverse effects of ICIs monotherapy as well as promising combination strategies, such as combinations with chemotherapy, radiotherapy, and anti-angiogenic drugs, etc. In addition, the methods of patient selection and response assessment will be summarized to assist clinical practice and further studies.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords